How a protein called TRAF3 affects B cell signaling in autoimmune diseases
Regulation of B cell signaling in autoimmunity by TRAF3
This study is looking at how a protein called TRAF3 affects B cells, which are important for our immune system, to find new ways to help people with autoimmune diseases and reduce the risk of certain cancers, using mice to learn more about how TRAF3 works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-10877031 on NIH RePORTER |
What this research studies
This research investigates the role of TRAF3, an adaptor protein, in regulating B cell signaling pathways that contribute to autoimmune diseases and the risk of developing B cell lymphoma. By understanding how TRAF3 functions in B cells, the research aims to identify new therapeutic strategies that can alleviate autoimmune symptoms without causing widespread immunosuppression. The study utilizes preclinical mouse models to explore the effects of TRAF3 deficiency on B cell survival and function, which may lead to better-targeted treatments for patients with chronic inflammatory conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from autoimmune diseases characterized by the involvement of autoreactive B cells, such as lupus or rheumatoid arthritis.
Not a fit: Patients with autoimmune conditions that do not involve B cell dysfunction or those who are not responsive to B cell-targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that specifically target harmful B cell activity in autoimmune diseases, improving patient outcomes without compromising overall immune function.
How similar studies have performed: Previous research has shown promising results in targeting specific B cell functions in autoimmune diseases, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Bishop, Gail a. — University of Iowa
- Study coordinator: Bishop, Gail a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.